Shandong Buchang Pharmaceuticals (603858.SH) donated medicines and cash totaling 37.6621 million yuan.
Stride Pharmaceutical (603858.SH) announced that recently, the company and its wholly-owned subsidiary Shandong Stride Pharmaceutical Sales Co., Ltd...
Shandong Buchang Pharmaceuticals (603858.SH) announced that recently, the company and its wholly-owned subsidiary Shandong Buchang Pharmaceutical Sales Co., Ltd., and its holding subsidiary Liaoning Aoda Pharmaceutical Co., Ltd. signed donation agreements with relevant public welfare organizations, donating a total of 37.6621 million yuan in medicines and cash for conducting public welfare activities.
In addition to this donation, from the date of the last disclosure of external donations (July 4, 2024) to the date of this announcement, the company and its holding subsidiary have cumulatively donated 3.8045 million yuan, including 318,100 yuan in donated medicines and 3.4864 million yuan in cash, mainly donated to public welfare organizations such as the Beijing Tongxin Gongzhu Public Welfare Foundation, the Beijing Union Medical College Foundation, the China Elderly Health Care Association, and the Beijing Liver and Gallbladder Care Public Welfare Fund for public welfare activities.
Related Articles

Shenzhen Dynanonic (300769.SZ) plans to carry out annual equipment maintenance and maintenance work.

Sinolink Medical Devices Industry 2026 Annual Strategy: Focus on two main areas of going global and innovation, pay attention to overseas expansion to accelerate the identification of stronger targets.

Guosen: In 2026, A-share companies will enter a transformation period of coordinated output in capacity, brand, and management systems. The "dumbbell-type" combination is the best configuration.
Shenzhen Dynanonic (300769.SZ) plans to carry out annual equipment maintenance and maintenance work.

Sinolink Medical Devices Industry 2026 Annual Strategy: Focus on two main areas of going global and innovation, pay attention to overseas expansion to accelerate the identification of stronger targets.

Guosen: In 2026, A-share companies will enter a transformation period of coordinated output in capacity, brand, and management systems. The "dumbbell-type" combination is the best configuration.

RECOMMEND





